Vanguard Group Inc. Decreases Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Vanguard Group Inc. trimmed its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 2.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,660,520 shares of the biotechnology company’s stock after selling 45,655 shares during the quarter. Vanguard Group Inc. owned 0.08% of Enanta Pharmaceuticals worth $18,548,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Tower Research Capital LLC TRC grew its stake in shares of Enanta Pharmaceuticals by 80.1% during the second quarter. Tower Research Capital LLC TRC now owns 2,026 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 901 shares during the last quarter. Clearstead Advisors LLC purchased a new stake in Enanta Pharmaceuticals in the third quarter worth $57,000. Royal Bank of Canada lifted its position in shares of Enanta Pharmaceuticals by 68.7% during the second quarter. Royal Bank of Canada now owns 2,665 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,085 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Enanta Pharmaceuticals by 146.7% during the second quarter. PNC Financial Services Group Inc. now owns 2,771 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 1,648 shares during the period. Finally, Captrust Financial Advisors grew its holdings in shares of Enanta Pharmaceuticals by 343.8% in the first quarter. Captrust Financial Advisors now owns 852 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 660 shares during the last quarter. Institutional investors own 94.99% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ENTA. JPMorgan Chase & Co. lowered their price objective on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Thursday, February 8th. StockNews.com lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, April 6th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $19.33.

Enanta Pharmaceuticals Stock Performance

NASDAQ ENTA opened at $16.45 on Monday. Enanta Pharmaceuticals, Inc. has a one year low of $8.08 and a one year high of $38.79. The firm has a market cap of $348.02 million, a PE ratio of -2.51 and a beta of 0.47. The firm’s fifty day moving average is $14.61 and its two-hundred day moving average is $11.63.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.18) by ($0.40). Enanta Pharmaceuticals had a negative net margin of 187.77% and a negative return on equity of 60.38%. The company had revenue of $18.00 million for the quarter, compared to analysts’ expectations of $22.74 million. Research analysts predict that Enanta Pharmaceuticals, Inc. will post -4.9 earnings per share for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.